CJC-1295 DAC vs Sermorelin
A side-by-side research comparison of CJC-1295 DAC and Sermorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | CJC-1295 DAC | Sermorelin |
|---|---|---|
| Full name | CJC-1295 with Drug Affinity Complex | Sermorelin Acetate (GHRH 1-29) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Previously FDA-approved (discontinued 2008) |
| Mechanism | The DAC moiety binds serum albumin creating a depot that slowly releases active CJC-1295 for continuous GHRH signaling. | Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH. |
| Molecular weight | 3,647 Da | 3,358 Da |
| Half-life | 8 days | 10-20 minutes |
| Bioavailability | High (SubQ) | Moderate (SubQ) |
| Typical dose | 2 mg | 200-300 mcg |
| Frequency | 1-2x per week | Once daily before bed |
| Route | Subcutaneous | Subcutaneous injection |
CJC-1295 DAC reported benefits
- Once/twice weekly dosing
- Sustained IGF-1 elevation
- Convenient schedule
- Long-term body composition changes
Sermorelin reported benefits
- Natural GH pulsatility preserved
- Improved sleep quality
- Body composition improvement
- Skin elasticity
- Long safety record
Related comparisons
Research and educational reference only. Not medical advice.